Conference Roundup

Most anti-VEGF injections for diabetic retinopathy have similar treatment intervals

Posted on

The average interval between injections of aflibercept (AFL), bevacizumab (BEVA), and ranibizumab (RAN) for patients with diabetic retinopathy (DR) is similar, according to a poster presented at ARVO 2022.

 In this retrospective cohort study, data from patients with DR who were injected unilaterally with AFL, BEVA, or RAN from July 2020 through June 2021 was used to calculate days between injections for each therapy.

 During the study period, there were 14,911 injections placed unilaterally for any diagnosis, of which 1313 injections were for DR. The average interval between injections for DR for all medications was 70 days.

The average intervals for BEVA, AFL, and RAN were 69 days (standard deviation [SD] +/- 56 days); 71 days (SD +/- 53 days); and 70 days (SD +/- 63 days), respectively.

Two tailed t-test for comparisons between medications yielded a P value of 0.591 for BEVA versus AFL; P = 0.886 for BEVA versus RAN; and P = 0.961 for AFL versus RAN.

Miller C, et al. Evaluation of the Mean Treatment Intervals for Various Anti-Vegf Injections in the Treatment of Diabetic Retinopathy. Presented at ARVO 2022.